GÖRG Partnerschaft von Rechtsanwälten mbB, led by Munich partner Dr. Bernt Paudtke, advised MIG Capital AG on an investment in iOmx Therapeutics AG. In addition to new investors, existing investors Wellington Partners, Sofinnova Partners and M Ventures also participated in the Series B financing round. A total of EUR 65 million was invested.
The new funds will be invested to conduct a phase 1 clinical trial for the lead programme IMT-07, a SIK3 kinase inhibitor for the treatment of solid tumours. In addition, IMT-18, a first-in-class IGSF11 antibody for the treatment of PD-1/PD-L1-resistant tumours, will be further developed. In addition, iOmx plans to identify further novel immune checkpoint targets via its proprietary platform iOTarg and develop drug candidates based on these.
Advisors MIG Capital AG
GÖRG Partnerschaft von Rechtsanwälten mbB
Dr. Bernt Paudtke, Partner, M&A / Corporate Law, Munich
Dr. Christian Glauer, Associated Partner, M&A / Corporate, Munich
Tobias Reichenberger, Associate, M&A / Corporate, Munich
Dr. Katharina Landes, Counsel, IP/IT, Cologne
Dr. Ulrich Fülbier, Partner, Labour and Employment Law, Munich
Johanna Hascher, Associate, Labour and Employment Law, Munich
Advisors iOmx Therapeutics AG
Allen & Overy LLP
Dr. Alexander Veith, Partner, M&A / Corporate Law, Munich
Dr. Jens Wagner, Counsel, M&A / Corporate, Munich
Linda Mayer, Associate, M&A / Corporate Law, Munich
About MIG Capital AG
MIG Capital AG (formerly MIG Verwaltungs AG) is one of the leading German VC investors. MIG invests through the MIG funds in young deep tech and life sciences companies in German-speaking Europe and beyond. The company has so far invested over €600 million in over 40 companies. MIG's portfolio companies develop innovations in areas such as biopharmaceuticals, artificial intelligence / machine learning, quantum technologies, digitization / IoT, precision medicine and digital health. The MIG investment portfolio currently consists of 28 companies.
MIG's investment team consists of a committed group of experts of engineers, biologists, scientists and investors who use analytical and creative processes to evaluate the risks and opportunities of business models and technologies. Their reputation, their experience and their network provide excellent access to companies, institutions and decision-makers in order to support the growth of their portfolio companies.
In recent years, MIG AG has successfully sold its portfolio companies SuppreMol (to Baxter in 2015), sunhill technologies (to Volkswagen in 2015), Ganymed (to Astellas in 2016) and Siltectra (to Infineon in 2018), and led BRAIN (in 2017), NFON (in 2018), BioNTech (in 2019) and Immatics (in 2020) to listings on stock exchanges.
About iOmx Therapeutics
iOmx Therapeutics (www.iomx.com) is a biopharmaceutical company focused on developing first-in-class cancer immunotherapies addressing novel immune checkpoints hijacked by cancer cells. Utilizing its iOTarg™ high-throughput screening platform, iOmx has identified a number of proprietary tumor-associated next-generation immune checkpoints and is advancing a preclinical stage pipeline of promising drug candidates that have the potential to address cancers that are resistant to current immunotherapies. The company’s lead program IMT-07 targets SIK3, an immune protective kinase in multiple solid tumors; the IMT-18 program is a first-in-class antibody designed to inhibit IGSF11, an immune checkpoint in PD-1/PD-L1-resistant tumors. Founded in 2016 based on the work of its scientific founders Philipp Beckhove, MD, and Nisit Khandelwal, Ph.D., conducted at the German Cancer Research Center, iOmx is backed by international venture capital investors, such as Wellington Partners, Sofinnova Partners and M Ventures as well as MIG Capital and Athos Service. iOmx is based in Martinsried/Munich, Germany.
